newsfilter
← Earnings
Earnings Releases·

Abeona Therapeutics — Third Quarter 2026 Earnings Summary

Abeona Therapeutics reported third-quarter 2026 net revenue of $13.5 million from ZEVASKYN, representing an 18% sequential increase. The company completed 15 ZEVASKYN treatments since launch, including six in the quarter, while expanding its qualified treatment center network to eight sites. Additionally, ZEVASKYN received New Technology Add-On Payment status effective October 1, 2026, and the company acquired the Phase 3-ready asset ABO-801 for eosinophilic esophagitis alongside securing $30 million in private placement financing.

Company
ABEONA THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology